

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 9/16, 9/50, 38/09</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/15154</b> <b>(43) International Publication Date:</b> 1 April 1999 (01.04.99)
<b>(21) International Application Number:</b> PCT/US98/19603 <b>(22) International Filing Date:</b> 21 September 1998 (21.09.98) <b>(30) Priority Data:</b> 08/935,452 24 September 1997 (24.09.97) US <b>(71) Applicant:</b> ALKERMES CONTROLLED THERAPEUTICS, INC. [US/US]; 4th floor, 64 Sidney Street, Cambridge, MA 02139 (US). <b>(72) Inventors:</b> TRACY, Mark, A.; 190 Hillside Avenue, Arlington, MA 02474 (US). HERBERGER, John, D.; 4009 Willow Creek Lane, Moore Park, CA 93021 (US). BURKE, Paul, A.; 261 Melrose Drive, Oxnard, CA 93035 (US). HERBERT, Paul, F.; 4 Oak Hill Road, Wayland, MA 01778 (US). <b>(74) Agents:</b> ELMORE, Carolyn, S. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHODS FOR FABRICATING POLYMER-BASED CONTROLLED RELEASE PREPARATIONS  <b>(57) Abstract</b>  The present invention relates to a polymer-based sustained release device, and methods of forming and using the device for the sustained release of an active agent. The improved method of the invention for forming a polymer-based sustained release device comprises forming a polymer/active agent solution by mixing a polymer, a continuous phase, and an active agent. The continuous phase can comprise one or more polymer solvents, a polymer solvent/polymer non-solvent mixture, or a polymer solvent/active agent non-solvent mixture. When the continuous phase comprises a polymer solvent/active agent non-solvent, the active agent can also be present as a microparticulate rather than in solution. The continuous phase is then removed from the polymer/active agent solution, thereby forming a solid polymer/active agent matrix.		

ATTORNEY DOCKET NUMBER: 10271-021-999  
SERIAL NUMBER: 09/724,531  
REFERENCE: BG

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## METHODS FOR FABRICATING POLYMER-BASED CONTROLLED RELEASE PREPARATIONS

## BACKGROUND OF THE INVENTION

Many illnesses or conditions require administration of a constant or sustained  
5 level of a medicament or biologically active agent to provide the most effective  
prophylactic or therapeutic effect. This may be accomplished through a multiple  
dosing regimen or by employing a system that releases the medicament in a  
sustained fashion.

Systems for delivering sustained levels of medication have employed  
10 biodegradable materials, such as polymers, encapsulating the medicament. The use  
of biodegradable polymers, for example, in the form of microparticles or  
microcarriers, provides a sustained release of medicaments, by utilizing the inherent  
biodegradability of the polymer to control the release of the medicament thereby  
providing a more consistent, sustained level of medication and improved patient  
15 compliance.

Certain methods of fabricating polymer-based sustained release devices  
comprise the steps of dissolving a polymer in a solvent, adding to the polymer  
solution the active agent to be incorporated and removing the solvent from the  
mixture thereby forming a matrix of the polymer with the active agent distributed  
20 throughout the matrix.

Many of these methods of fabricating polymer-based sustained release  
devices employ a solvent or mixture of solvents, which solubilizes the polymer, but  
are not capable of solubilizing the active agent to be incorporated. Hence, these  
methods have disadvantages, for example, in the lack of suitable solvents which are  
25 capable of dissolving both active agent and polymer and which are non-toxic,  
biocompatible and can be readily removed from the final product; in solubilizing of  
the active agent in an active form; and in optimizing encapsulation efficiency of the  
active agent to achieve a device with the desired release characteristics.

Therefore, a need exists for improved methods for fabricating a polymer-based sustained release device, particularly devices having a high load of active agent.

#### SUMMARY OF THE INVENTION

5       The present invention is based upon the discovery that an improved polymer-based sustained release device can be achieved when a continuous phase which is capable of solubilizing both the polymer and the active agent is employed in the method for fabricating the device. Unexpectedly, an advantage of the sustained release devices obtained thereby is that they can have a very high load of active  
10   agent. For example, the device can achieve a relative weight of active agent in excess of the total polymer weight (e.g., present at about 50% by weight or more of the total weight of the device) with improved encapsulation efficiency and improved sustained release characteristics.

      An additional advantage of the invention is that it allows for the preparation  
15   of small microparticles which contain encapsulated drug and exhibit improved delivery characteristics. A further advantage is the ability to use solubility properties of the active agent to affect particle size of the active agent, further enabling improved delivery characteristics. Additionally, the process for preparing microparticles may be improved by permitting the ability to filter sterilize process  
20   components or facilitate atomization of the polymer/active agent solution or dispersion.

      The present invention thus relates to a polymer-based sustained release device, and methods of forming and using said device for the sustained release of an active agent. The improved method of the invention, for forming the polymer-based  
25   sustained release device, utilizes a continuous phase which comprises, for example, one or more polymer solvents, a polymer solvent/polymer non-solvent mixture or a polymer solvent/active agent non-solvent mixture, to dissolve the polymer and also solubilize the active agent in the polymer solution. Also embraced by the invention described herein is a process wherein the continuous phase comprises a polymer  
30   solvent/active agent non-solvent mixture and the active agent is present as a microparticulate. For purposes of the invention, the term "microparticulate"

describes the situation where the active agent is dispersed in the continuous phase at a concentration of the active agent approaching solubilization of the active agent or where the active agent is present as a combination of both dispersed particulate and solubilized active agent. Typically, the microparticulate is formed by mixing an active agent non-solvent with a solution containing the active agent which thereby leads to partial or complete precipitation of the active agent (also referred to as the "Microparticulate Method").

In one embodiment, the method comprises (a) forming a polymer/active agent solution by mixing a polymer, a continuous phase comprising one or more polymer solvents and an active agent wherein the polymer and active agent are present in relative concentrations such that the final product contains about 50% by weight or more of active agent; and (b) removing the continuous phase of step (a) thereby forming a solid polymer/active agent matrix.

The method can further comprise the step of forming droplets of the polymer/active agent solution prior to removal of the continuous phase. Further, the method can comprise freezing the droplets prior to removal of the continuous phase. According to the method of the invention the droplets can be microdroplets. In a specific embodiment wherein droplets are formed and then frozen, the continuous phase can be removed by an extraction process. Alternatively, the continuous phase can be removed by an evaporation process or a combination of an evaporation and extraction process.

When the continuous phase comprises one or more polymer solvents any combination of polymer solvents which is miscible and allows both the polymer and active agent to be dissolved, is suitable for use in the invention. Dimethylsulfoxide (also referred to as DMSO) is preferred because it is a good solvent for many polymers and active agents, including water-soluble agents such as peptides, antigens, and small molecule drugs. Other suitable solvents, in particular for PLGA polymers include, DMSO, ethyl acetate, methyl acetate, methylene chloride, chloroform, hexafluoroisopropanol, acetone, and combinations thereof. Preferably, the polymer solvent is pharmaceutically acceptable.

In another embodiment, the method for forming a polymer-based sustained release device comprises the steps of: (a) forming a polymer/active agent solution

by mixing a polymer, an effective amount of an active agent and a continuous phase comprising a polymer solvent/polymer non-solvent mixture wherein the amount of polymer non-solvent is dictated by achieving solubilization of the active agent without causing substantial precipitation of the polymer; and (b) removing the  
5 continuous phase of step (a) from the polymer/active agent solution, thereby forming a solid polymer/active agent matrix. In a further embodiment, the active agent is present at a concentration such that the final product or device contains about 50% by weight or more of active agent.

The method can further comprise the step of forming droplets of the  
10 polymer/active agent solution prior to removal of the continuous phase. Further, the method can comprise freezing the droplets prior to removal of the continuous phase. According to the method of the invention the droplets can be microdroplets. In a specific embodiment wherein droplets are formed and then frozen, the continuous phase can be removed by an extraction process. Alternatively, the  
15 continuous phase can be removed by evaporation process or a combination of an evaporation and extraction process.

The polymer non-solvent can be selected such that it is miscible with the polymer solvent, does not cause substantial precipitation of the polymer and is not deleterious to the active agent. Preferably, the polymer solvent and the polymer  
20 non-solvent are pharmaceutically acceptable.

Suitable polymer non-solvents include, for example, ethanol, methanol, water, acetonitrile (MeCN), dimethylformamide (DMF), ethyl ether, alkanes such as pentane, isopentane, hexane, heptane and oils, such as mineral oils, fish oils, silicone oils, vegetable oils, or combinations thereof. Vegetable oils, such as olive oil,  
25 sesame oil, soybean oil, safflower oil, peanut oil, cottonseed oil, coconut oil, linseed oil, corn oil, castor oil, palm oil, or combinations thereof, are preferred for use in the invention. In particular embodiments, the polymer solvent is DMSO and the non-solvent is ethanol or water.

In another embodiment, the method for forming a polymer-based sustained  
30 release device comprises the steps of: (a) forming a polymer/active agent mixture by mixing a polymer, an effective amount of an active agent and a continuous phase comprising a polymer solvent/active agent non-solvent mixture wherein the amount

of active agent non-solvent is dictated by achieving solubilization of the active agent, or alternatively achieving the active agent as a microparticulate in the continuous phase containing the polymer; and (b) removing the continuous phase of step (a) thereby forming a solid polymer/active agent matrix. In a further  
5 embodiment, the active agent is present at a concentration such that the final product or device contains about 50% by weight or more of active agent.

The method can further comprise the steps of forming droplets of the polymer/active agent solution prior to removal of the continuous phase. Further, the method can comprise freezing the droplets prior to removal of the continuous phase.  
10 According to the method of the invention the droplets can be microdroplets. In a specific embodiment wherein droplets are formed and then frozen, the continuous phase can be removed by an extraction process. Alternatively, the continuous phase can be removed by evaporation process or a combination of an evaporation and extraction process.

15 The active agent non-solvent can be selected such that it is miscible with the polymer solvent, does not substantially precipitate the polymer, and is not deleterious to the active agent. Suitable active agent non-solvents are dependent upon the properties of the active agent and for peptides can include, for example, acetone, ethanol and methylene chloride.

20 In another aspect, the invention relates to a polymer-based sustained release device prepared according to the method of the invention. The device comprises a polymeric matrix and an active agent dispersed within the matrix. The device formed by the method of the invention exhibits a unique microstructure, the porosity of which varies as a function of load, polymer concentration and the type of  
25 continuous phase employed.

The method of using the polymer-based sustained release device of the present invention comprises providing a sustained delivery of active agent, in a subject, over a therapeutically useful period of time, by administering to the subject a dose of said polymer-based sustained release device. The invention also provides  
30 methods for preparing microparticles of varying size and/or morphology for use in specific applications, for example, applications such as chemoembolization, vaccine

delivery or cellular uptake where the size of the microparticles directly impacts performance.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a plot of the percent of animals per treatment group in diestrus for groups of rats treated with microparticles prepared using the Particulate Method, as described herein, and having the indicated load of azaline B versus time.

Figure 2 is a plot of the percent of animals per treatment group in diestrus for groups of rats treated with microparticles having the indicated load of azaline B prepared using the method of the invention, according to Examples 1 and 3, as described herein, and having the indicated load of azaline B, versus time.

Figure 3 is a plot of serum concentrations (ng/ml) of azaline B for groups of animals treated with azaline B containing microparticles prepared by using the Particulate Method and the method of the invention, according to Examples 1 and 3, as described herein, and having the indicated load of azaline B, versus time.

#### DETAILED DESCRIPTION OF THE INVENTION

The features and other details of the invention will now be more particularly described and pointed out here as well as in the claims. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principle features of this invention can be employed in various embodiments without departing from the scope of the invention.

A solution, as defined herein, is a mixture of one or more substances (referred to as the solute, for example, the polymer and the active agent) dissolved in one or more other substances (referred to as the solvent or solvents, for example, DMSO or a combination of DMSO and methylene chloride). For purposes of this invention, the "continuous phase" refers to the major component of a solution, such as a polymer solvent or a mixture thereof, and a mixture of a polymer solvent and a non-solvent.



-7-

The term "non-solvent," as used herein, refers to a material, which does not substantially dissolve a second or reference material. For purposes of this invention, the non-solvent can be a non-solvent for the active agent or the polymer.

The term "microdroplet," as used herein, refers to a droplet of any  
 5 morphology which has a dimension less than or equal to about 1000  $\mu\text{m}$ .

The active agent, azaline B, used in many of the examples described herein is an LHRH peptide analog, the structure of which is described in, for example, Campen *et al.*, *Biochemical Pharmacology* 40: 1313-1321, 1995, and which can be depicted as follows:

10 Ac-D-Nal<sup>1</sup> - D-Cpa<sup>2</sup> - D-Pal<sup>3</sup> - Ser<sup>4</sup> - Aph<sup>5</sup>(atz) -

D-Aph<sup>6</sup>(atz) - Leu<sup>7</sup> - Ilys<sup>8</sup> - Pro<sup>9</sup> - D-Ala<sup>10</sup>

(Ac=acetyl, Nal=3-(2'-naphthyl)-alanine, Cpa=4-chloro-phenylalanine, Pal=3-(3'-pyridyl)-alanine, Aph=4-amino-phenylalanine, atz= 5'-(3'-amino-1*H*-1',2',4'-triazolyl), Ilys=N'-isopropyl-lysine). The azaline B can also be in the form of salt,

15 such as the acetate salt.

In one aspect, the invention provides an improved method for preparing a polymer-based sustained release device comprising the use of a continuous phase which comprises one or more polymer solvents, a mixture of one or more polymer solvents with one more polymer non-solvents or a mixture of one or more polymer  
 20 solvents with one or more active agent non-solvents, to dissolve the polymer and also solubilize the active agent in the polymer solution. When the continuous phase comprises a polymer solvent/active agent non-solvent, the situation where the active agent is present as a microparticulate is also embraced within the invention described herein.

25 In one embodiment, the method comprises (a) forming a polymer/active agent solution by mixing a polymer, a continuous phase comprising one or more polymer solvents and an active agent wherein polymer and active agent are present in relative concentrations such that the final product or device contains about 50% by weight or more of active agent; and (b) removing the continuous phase of step (a)  
 30 thereby forming a solid polymer/active agent matrix.

The method can further comprise the step of forming droplets of the polymer/active agent solution prior to removal of the continuous phase. Further the

method can comprise freezing the droplets prior to removal of the continuous phase. According to the method of the invention the droplets can be microdroplets. In a specific embodiment wherein droplets are formed and then frozen, the continuous phase can be removed by an extraction process. Alternatively, the continuous phase  
5 can be removed by evaporation process or a combination of an extraction and evaporation process.

When the continuous phase comprises one or more polymer solvents any combination of polymer solvents which is miscible and allows both the polymer and active agent to be dissolved, is suitable for use in the invention. Dimethylsulfoxide  
10 (also referred to as DMSO) is a preferred solvent because it is a good solvent for many polymers and active agents, including peptides, antigens and small molecule drugs. Other suitable solvents, in particular for PLGA polymers, include, for example, DMSO, ethyl acetate, methyl acetate, methylene chloride, chloroform, hexafluoroisopropanol and acetone. Preferably, the polymer solvent is  
15 pharmaceutically acceptable.

The method wherein one or more polymer solvents can be used as the continuous phase can be referred to herein as the "Polymer Solvent Method" indicating that the major component of the continuous phase of the method comprises, or consists essentially of, one or more polymer solvents. If more than  
20 one polymer solvent is employed, it is understood that one of the polymer solvents can also be a non-solvent for the active agent provided that the active agent remains soluble in the continuous phase.

In another embodiment, the method for forming a polymer-based sustained release device comprises the steps of: (a) forming a polymer/active agent solution  
25 by mixing a polymer, an effective amount of an active agent and a continuous phase comprising a polymer solvent/polymer non-solvent mixture wherein the amount of non-solvent is dictated by achieving solubilization of the active agent without causing substantial precipitation of the polymer; and (b) removing the continuous phase of step (a) from the polymer/active agent solution, thereby forming a solid  
30 polymer/active agent matrix. In a further embodiment, the active agent is present at a concentration such that the final product or device contains about 50% by weight or more active agent.

The method can further comprise the step of forming droplets of the polymer/active agent solution prior to removal of the continuous phase. Further, the method can comprise freezing the droplets prior to removal of the continuous phase. According to the method of the invention the droplets can be microdroplets. In a  
5 specific embodiment wherein droplets are formed and then frozen, the continuous phase can be removed by an extraction process. Alternatively, the continuous phase can be removed by evaporation process or a combination of an extraction and evaporation process.

The method wherein the continuous phase comprises a polymer  
10 solvent/polymer non-solvent mixture, can be referred to as the "Polymer Solvent/Polymer Non-Solvent Method." When the major component of the continuous phase comprises, or consists essentially of, a polymer solvent/polymer non-solvent mixture a combination or one or more polymer solvents with one or more polymer non-solvents can be employed. The amount and type of polymer non-  
15 solvent can be selected such that it is completely or substantially miscible with the polymer solvent, does not cause substantial precipitation of the polymer, and is not deleterious to the active agent. Preferably, the polymer solvent and the polymer non-solvent are pharmaceutically acceptable. It is understood that one or both solvents in the continuous phase can serve to solubilize the active agent.

20 Polymer non-solvents suitable for use in the invention include, for example, ethanol, methanol, water, acetonitrile (MeCN), dimethylformamide (DMF), ethyl ether, alkanes, such as pentane, isopentane, hexane or heptane, and oils, such as mineral oils, fish oils, silicone oil, vegetable oils, or any combination thereof. Vegetable oils, such as olive oil, sesame oil, soybean oil, safflower oil, peanut oil,  
25 cottonseed oil, coconut oil, linseed oil, corn oil, castor oil, palm oil, or combinations thereof, are preferred for use in the invention. In particular embodiments, the polymer solvent is DMSO and the non-solvent is ethanol or water.

In another embodiment, the method for forming a polymer-based sustained release device comprises the steps of: (a) forming a polymer/active agent mixture  
30 by mixing a polymer, an effective amount of an active agent and a continuous phase comprising a polymer solvent/active agent non-solvent mixture wherein the amount of active agent non-solvent is dictated by achieving solubilization of the active

-10-

agent, or alternatively achieving the active agent as a microparticulate, in the continuous phase containing the polymer; and (b) removing the continuous phase of step (a) thereby forming a solid polymer/active agent matrix. In a further embodiment, the active agent is present at a concentration such that the final product or device contains about 50% by weight or more of active agent.

The method can further comprise the step of forming droplets of the polymer/active agent solution prior to removal of the continuous phase. Further, the method can comprise freezing the droplets prior to removal of the continuous phase. According to the method of the invention the droplets can be microdroplets. In a specific embodiment wherein the droplets are formed and then frozen, the continuous phase can be removed by an extraction process. Alternatively, the continuous phase can be removed by an evaporation process or a combination of an extraction and evaporation process.

The amount and type of active agent non-solvent can be selected such that it is miscible with the polymer solvent, does not substantially precipitate the polymer, and is not deleterious to the active agent. Suitable active agent non-solvents are dependent upon the properties of the active agent and for peptides can include, for example, acetone, ethanol and methylene chloride.

Other excipients can be present in the polymer/active agent solution, as described below. These excipients need not be soluble in the continuous phase, although, this is preferred.

The active agent of the invention can be added either as a solid (such as in a fine powder) or neat liquid, or as a solution of the active agent in the polymer solvent or polymer non-solvent.

It can be desirable to add a polymer non-solvent which is a solvent for the active agent to the polymer solvent when forming the polymer/active agent solution if, for example, the polymer solvent does not solubilize the active agent to the desired degree. The polymer non-solvent should be miscible with the polymer solvent, aid in solubilizing the active agent, not cause substantial precipitation of the polymer and not be deleterious to the active agent. An example of such an embodiment is in the formation of a solution of PLGA and tRNA. DMSO is a good solvent for PLGA but poorly solubilizes tRNA. The inclusion of, for example,

water (a good solvent for tRNA, miscible with DMSO and a non-solvent for the polymer) results in an optically transparent solution comprising PLGA, tRNA, DMSO and water. Therefore, the continuous phase, in this embodiment, comprises a polymer solvent/non-solvent mixture, wherein the non-solvent is a non-solvent for the polymer. The amount of polymer non-solvent included is at least that amount necessary to achieve the desired level of solubilization of the active agent but not to exceed that amount which causes substantial precipitation of the polymer.

It can also be desirable to add a polymer non-solvent, which is a non-solvent for the active agent, to the polymer solvent when forming the polymer/active agent solution, if, for example, the polymer solvent solubilizes the active agent to a greater degree than desired. For example, in such an embodiment, the active agent may "leach" out of the microdroplet with the polymer solvent during the extraction step of the process. The addition of the active agent non-solvent can minimize this effect. The polymer non-solvent should be miscible with the polymer solvent and assist in decreasing the solubility of the active agent in the resulting polymer solvent/non-solvent mixture.

In summary, one aspect of the invention relates to maximizing polymer and active agent solubility properties in the continuous phase by selecting the appropriate solvent or combination of solvents. Thus, the addition or selection of appropriate solvents, co-solvents, or non-solvents results in the improved microparticles described herein.

The continuous phase can be formed prior to, following or simultaneous with the addition of the polymer to the polymer solvent. The active agent can be mixed with the polymer solution either as a solid, a neat liquid or in solution. When the active agent is added in solution the solvent of the active agent solution can be a polymer non-solvent, polymer solvent or combinations thereof. Further, when the active agent is added as a solid or neat liquid, which is not soluble in the polymer solution, an additional polymer solvent, polymer non-solvent or combinations thereof can be added which solubilizes the active agent.

For example, poly(lactide-co-glycolide) was dissolved in DMSO and the active agent, ovalbumin, was predissolved in a minimum amount of water (a polymer non-solvent) and added to the polymer solution to form the polymer/active

agent solution, thereby providing a continuous phase comprising a polymer solvent/polymer non-solvent mixture.

In another example, poly(lactide-co-glycolide) was dissolved in DMSO and the active agent, tRNA, was predissolved in a minimum amount of water and added  
5 to the polymer solution to form the polymer/active agent solution.

In yet another embodiment, the active agent can be added as a solid, to a mixture of polymer solvent/polymer non-solvent having the polymer dissolved therein. The solid is soluble in the mixture. In a specific embodiment, the continuous phase comprising the polymer solvent/polymer non-solvent mixture, is  
10 DMSO and ethanol. In a more specific embodiment, the polymer of the polymer solution includes poly(lactide-co-glycolide) dissolved in a DMSO/ethanol mixture and the active agent is azaline B. In each of these embodiments, the result was a single continuous phase in which both the polymer and active agent were solubilized, thereby avoiding prior art processes which are characterized by two or  
15 more phases. The solvents and/or non-solvents can be added in a wide range of relative amounts, including for example about 1:10 to about 10:1 or about 1:3 to about 3:1, by volume, as is appropriate.

After the polymer/active agent solution is formed it can be processed to form microdroplets. These microdroplets can then be frozen by means suitable to form  
20 microparticles. Examples of means for processing the polymer/active agent solution to form droplets include directing the solution through an ultrasonic nozzle, pressure nozzle, Rayleigh jet, or by other means known for creating droplets from solution such as those described in U.S. Patent No. 5,019,400, issued to Gombotz *et al.*, co-pending U.S. Patent Application No. 08/443,726, filed May 18, 1995, and co-  
25 pending U.S. Patent Application No. 08/649,128, filed May 14, 1996, the teachings of all of which are incorporated herein by reference in their entirety.

The microdroplets are then frozen by means suitable to form microparticles. Means suitable for freezing droplets to form microparticles include directing the droplets into or near a liquified gas, such as liquid argon and liquid nitrogen to form  
30 frozen microdroplets which are then separated from the liquid gas. The frozen microdroplets are then exposed to an extraction solvent or curing solvent or phase, which is generally a poor solvent for the polymer, which has a lower melting point

than the continuous phase and which has sufficient miscibility with the continuous phase to extract solid and/or thawed continuous phase from a frozen microparticle.

In one method the liquified gas overlays frozen extraction solvent, as described in U.S. Patent No. 5,019,400, issued to Gombotz *et al.*, the entire content of which is incorporated herein by reference. In a second method, the liquified gas and cold extraction solvent are maintained in a distinct "freezing zone" and "extraction zone," as described in co-pending U.S. Patent Application No. 08/443,726, filed May 18, 1995, the content of which is incorporated herein in its entirety. As stated above, the purpose of the extraction solvent is to remove or extract, as solid and/or a liquid, any continuous phase in the frozen microdroplets, thereby forming active agent containing microparticles. Typically, the extraction solvent or curing phase is selected from one or more of the polymer non-solvents discussed above. It can be the same or different as any polymer non-solvent employed in the continuous phase, as described herein. It can optionally further include an active agent non-solvent as well. Typical extraction solvents include, for example, ethanol, methanol, ethyl ether, alkanes such as pentane, isopentane, hexane, heptane, and oils such as mineral oils, fish oils, silicone oil, vegetable oils, or combinations thereof. Vegetable oils, such as olive oil, sesame oil, soybean oil, safflower oil, peanut oil, cottonseed oil, coconut oil, palm oil or combinations thereof, are preferred. It is generally desirable that the extraction solvent(s) or curing phase possess a melting point the same or, preferably, lower than the continuous phase. Thus, the extraction step can be conducted or initiated at a temperature at which the extraction solvent(s) or curing phase is a liquid and the microdroplets (including the continuous phase) are frozen. Mixing ethanol with other suitable extraction solvents, such as an alkane, including hexane, heptane or pentane, can directly impact the encapsulation efficiency, morphology, and consistency therein of the resulting microspheres as well as cause an unexpected increase in the rate of solvent extraction, above that achieved by ethanol alone, from certain polymers, such as poly(lactide-co-glycolide) polymers.

In another method the polymer/active agent matrix, as formed above, is fragmented at a temperature below the glass transition temperature of the polymer/active agent matrix, thereby forming polymer/active agent microparticles,

as described in co-pending U.S. Patent Application 08/649,128, filed May 14, 1996 the entire teachings of which are incorporated herein by reference in their entirety.

A wide range of sizes of polymer-based sustained release devices can be made by varying the droplet size, for example, by changing the ultrasonic nozzle frequency or diameter. If larger devices are desired, the polymer/active agent solution can be processed by passage through a syringe or the like directly into the cold liquid. Alternatively, the solution can be dripped or otherwise added to the cold liquid. Increasing the viscosity of the polymer/active agent solution can also increase device size. The size of the devices which can be produced by the method of the invention are, for example, microparticles ranging from greater than about 1000 to about 1 micrometer in diameter.

The term "polymer-based sustained release device," as defined herein, comprises a polymer and an active agent (also referred to herein as a "polymer/active agent matrix"). The polymers of the present invention are generally biocompatible. Suitable biocompatible polymers can be either biodegradable or non-biodegradable polymers, or blends or copolymers thereof.

A polymer is biocompatible if the polymer, and any degradation products of the polymer, are substantially non-toxic to the recipient, and also presents no unacceptable, deleterious or untoward effects on the recipient's body, such as a significant immunological reaction at the site of administration.

Biodegradable, as defined herein, means the composition will degrade or erode *in vivo* to form smaller chemical species which are biometabolizable and/or excretable. Degradation can result, for example, by enzymatic, chemical and/or physical processes. Suitable biocompatible, biodegradable polymers include, for example, poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, polycaprolactone, polycarbonates, polyesteramides, polyanhydrides, poly(amino acids), polyorthoesters, polyacetals, polycyanoacrylates, polyetheresters, poly(dioxanone)s, poly(alkylene alkylates)s, copolymers of polyethylene glycol and polyorthoester, biodegradable polyurethanes, blends and copolymers thereof.

Biocompatible, non-biodegradable polymers suitable for a sustained release device include non-biodegradable polymers selected from the group consisting of



polyacrylates, polymers of ethylene-vinyl acetates and acyl substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), chlorosulphonate polyolefins, polyethylene oxide, blends and copolymers thereof.

- 5 Further, the terminal functionalities or pendant groups of the polymers can be modified, for example, to modify hydrophilicity, hydrophobicity and/or provide, remove or block moieties which can interact with the active agent (via, for example, ionic or hydrogen bonding).

- Acceptable molecular weights for polymers used in this invention can be  
10 determined by a person of ordinary skill in the art taking into consideration factors such as the desired polymer degradation rate, physical properties such as mechanical strength, and rate of dissolution of polymer in solvent. Typically, an acceptable range of molecular weights is between about 2,000 Daltons to about 2,000,000 Daltons. In a preferred embodiment, the polymer is a biodegradable polymer or  
15 copolymer. In a more preferred embodiment, the polymer is a poly(lactide-co-glycolide) (hereinafter "PLGA").

- The term "active agent," as defined herein, is an agent, or its pharmaceutically acceptable salt, which when released *in vivo*, possesses the desired biological activity, for example therapeutic, diagnostic and/or prophylactic  
20 properties *in vivo*. Examples of suitable biologically active agents include proteins such as immunoglobulins, antibodies, cytokines (e.g., lymphokines, monokines, chemokines), interleukins, interferons, erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors, insulin, enzymes (e.g. superoxide dismutase, a plasminogen activator), tumor suppressors, blood proteins, hormones and hormone  
25 analogs (e.g., growth hormone, adrenocorticotrophic hormone, luteinizing hormone releasing hormone (LHRH) and azaline B), vaccines (e.g., tumoral, bacterial and viral antigens), antigens, blood coagulation factors; growth factors; peptides such as protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules; oligonucleotides; and ribozymes. Small molecular weight  
30 agents suitable for use in the invention include, antitumor agents such as bleomycin hydrochloride, methotrexate and adriamycin; antibiotics such as gentamicin, tetracycline hydrochloride and ampicillin; antipyretic, analgesic and anti-

inflammatory agents; antitussives and expectorants such as ephedrine hydrochloride, methylephedrine hydrochloride, noscapine hydrochloride and codeine phosphate; sedatives such as chlorpromazine hydrochloride, prochlorperazine hydrochloride and atropine sulfate; muscle relaxants such as tubocurarine chloride; antiepileptics such as sodium phenytoin and ethosuximide; antiulcer agents such as metoclopramide; antidepressants such as clomipramine; antiallergic agents such as diphenhydramine; cardiotonics such as theophyllol; antiarrhythmic agents such as propranolol hydrochloride; vasodilators such as diltiazem hydrochloride and bamethan sulfate; hypotensive diuretics such as pentolinium and ecarazine hydrochloride; antidiuretic agents such as metformin; anticoagulants such as sodium citrate and sodium heparin; hemostatic agents such as thrombin, menadione sodium bisulfite and acetomenaphthone; antituberculous agents such as isoniazide and ethambutol; hormones such as prednisolone sodium phosphate and methimazole; and narcotic antagonists such as nalorphine hydrochloride.

The amount of active agent which is contained in the polymer-based sustained release device is a therapeutically or prophylactically effective amount which can be determined by a person of ordinary skill in the art taking into consideration factors such as body weight, condition to be treated, type of device used, and release rate from the device.

A polymeric drug delivery device of the invention can contain from about 0.01% (w/w) to about 90% (w/w) of active agent (total weight of polymer/active agent). The amount of agent can vary depending upon the desired effect of the agent, the planned release levels, and the time span over which the agent is to be released. A low range of agent loading can be from about 0.1% (w/w) to about 30% (w/w). In treatments where a low range of agent loading is desired a preferred range is from about 0.5% (w/w) to about 20% (w/w). A high range of agent loading is that greater than or equal to about 50%. In treatments where a high range of agent loading is employed a preferred range is from about 50% (w/w) to about 85% (w/w) and more preferably from about 50% (w/w) to about 70% (w/w).

A sustained release of active agent is a release which occurs over a period of time longer than that which would be obtained following similar administration of the active agent as a dispersion or solution in a carrier. Generally, the sustained

release device can deliver the active agent for at least about seven days and, preferably, up to about three months.

The polymer-based sustained release device of this invention can be formed into many shapes such as a film, a pellet, a cylinder, a wafer, a disc or a  
5 microparticle. A microparticle, generally has a diameter of less than about one millimeter. A microparticle can have a generally spherical, non-spherical or irregular shape. Typically, the microparticle will be of a size suitable for injection. A preferred size range for microparticles is from about 1 to about 250 microns in diameter. The sustained release device in the form of a wafer or disc, for example,  
10 will typically be of a size suitable for implantation and, for example, can be manufactured by compressing microparticles.

The present invention can be used to incorporate and deliver a wide variety of active agents. Most often, the composition of the present invention will be used to deliver an active agent to a human or other animal for purposes of therapy,  
15 prophylaxis, hygiene, analgesics, cosmetics or the like. Such uses where the compositions are delivered to a human or other animal will generally be referred to as *in vivo* uses. The composition of the present invention will also have *in vitro* uses where an active substance is being delivered to an environment or system other than a human or animal such as in the sustained release of agrochemicals or in  
20 diagnostics. One of the major *in vivo* uses for the composition of the present invention will be for the delivery of drugs and other pharmaceutical agents in human and veterinary applications. For both *in vivo* and *in vitro* uses, the compositions will deliver the active substance to a surrounding environment.

Unexpectedly, the above process resulted in the ability to form sustained  
25 delivery devices even at very high loads (greater than or equal to at least about 50% (w/w)) with improved release characteristics and duration of release, as illustrated, for example, in Figures 1 and 2. It was also found that the morphology of the device changed with the amount, or load, of the active agent. The device, or microparticle, was porous at low loads (e.g, 10% to 30%), similar to the microparticles obtained in  
30 the known processes. However, at high loads (e.g. 50% to 90%), the microparticles were dense. Thus, the invention includes microparticles or sustained release devices manufactured by the process of the invention.

The invention also includes an improved sustained release device which has incorporated therein an amount of active agent greater than or equal to at least about 50% by weight (w/w) of the polymer-based sustained release device (also referred to as a "high load"). A preferred range is from about 50% (w/w) to about 85% (w/w) and more preferably from about 50% (w/w) to about 70% (w/w). In general, these high load microparticles are difficult to manufacture employing the prior art processes and the high encapsulation efficiency observed is unexpected. In addition, the high load microparticles would not be expected to exhibit improved sustained release of active agent over lower active agent loads. In a specific embodiment, the polymer-based sustained release device has a high load of azaline B. In a more specific embodiment, the polymer of the sustained release device is poly(lactide-co-glycolide) having a high load of azaline B.

In a further embodiment, the improved polymer-based sustained release device has an increased period of sustained release and/or increased bioavailability over that achieved with a device prepared by a method which does not solubilize the active agent in the polymer solution. For example, when microparticles containing azaline B are prepared employing methylene chloride as the sole polymer solvent the active agent is not solubilized (referred to herein as the "Particulate Method"). Comparison of active agent release from these microparticles with those prepared employing DMSO as the continuous phase (active agent solubilized) can be achieved by comparing Figures 1 and 2. Clearly, the polymer-based sustained release devices prepared by the process wherein the active agent is solubilized (Figure 2), demonstrate an increased period of sustained release over those devices wherein a single polymer solvent which does not solubilize the active agent is employed (Figure 1).

Without being bound by a particular theory it is believed that the release of the biologically active agent can occur by at least two different mechanisms. First, release can occur due to degradation of the polymer. Second, biologically active agent can be released by diffusion through the channels generated in the polymer-based sustained release device, such as by the dissolution of the active agent or by voids or pores created by the removal of the polymer/active agent solvent during the synthesis of the drug delivery device.

The rate of degradation can be controlled by changing polymer properties that influence the rate of hydration and/or degradation of the polymer. These properties include, for instance, the ratio of different monomers, such as lactide and glycolide, comprising a polymer; the use of the L- or D- isomer or racemic mixture of a chiral monomer; a polymer, such as a poly(lactide-co-glycolide) polymer that has, for instance, a hydrophobic or a hydrophilic end group; the morphology of the particle as impacted for example, by choice of solvents for polymer during preparation; and the molecular weight of the polymer. These properties can affect hydrophilicity and crystallinity, which control the rate of hydration of the polymer.

Hydrophilic excipients such as salts, carbohydrates and surfactants can also be incorporated to increase hydration and which can alter the rate of erosion of the polymer.

In addition, the active agent in the sustained release device of the present invention can also contain other excipients, such as stabilizers, bulking agents or aggregation-stabilizing agents. Stabilizers are added to maintain the potency of the biologically active agent during device fabrication, storage and over the duration of the agent's release. Suitable stabilizers include, for example, carbohydrates, amino acids, fatty acids and surfactants which are known to those skilled in the art. For amino acids, fatty acids and carbohydrates, such as sucrose, lactose, mannitol, inulin, maltose, dextran and heparin, the mass ratio of carbohydrate to biologically active agent is typically between about 1:10 and about 20:1. For surfactants, such as polysorbates (e.g., Tween<sup>TM</sup>) and poloxamers and poloxamines (e.g., Pluronic<sup>TM</sup>), the mass ratio of surfactant to agent is typically between about 1:1000 and about 1:2.

Aggregation-stabilizing agents are agents which stabilize the biologically active agent against significant aggregation *in vivo* over the sustained release period. Typically an aggregation stabilizer reduces the solubility of the biologically active agent, precipitates out a salt of the agent or forms a complex of the agent. The aggregation stabilizer and the biologically active agent can be separately contained within the drug delivery device, such as a device containing particles of aggregation stabilizer and separate particles of biologically active agent, and/or can be combined together in complexes or particles which contain both the aggregation stabilizer and the biologically active agent.

The use of aggregation-stabilizing agents is also described in co-pending U.S. Patent Applications 08/478,502 and 08/483,318 both filed on June 7, 1995, and U.S. Patent Application 08/521,744, filed on August 31, 1995 the teachings of which are incorporated herein by reference in their entirety.

5       Metal cations can be suitable as aggregation-stabilizing agents. These metal cations include cations of transition metals, such as  $\text{Zn}^{+2}$ ,  $\text{Cu}^{+2}$ ,  $\text{Co}^{+2}$ ,  $\text{Fe}^{+3}$  and  $\text{Ni}^{+2}$ . The use of metal cations as aggregation-stabilizing agents, is also described in co-pending U.S. Patent Application 08/279,784, filed July 25, 1994, co-pending U.S. Patent Application 08/521,744, filed August 31, 1995, PCT Patent Application  
10 PCT/US95/07348, filed June 7, 1995, U.S. Patent No. 5,654,010 issued to Johnson *et al.* and U.S. Patent No. 5,667,800 issued to Johnson *et al.*, the teachings of which are incorporated herein by reference in their entirety.

The polymer-based sustained release device can also contain a metal cation component which is dispersed within the polymer. This metal cation component  
15 acts to modulate the release of biologically active agent from the polymeric matrix.

A metal cation component used in modulating release typically contains at least one type of multivalent metal cation. Examples of metal cation components suitable to modulate release of biologically active agent, include, or contain, for instance,  $\text{Mg}(\text{OH})_2$ ,  $\text{MgCO}_3$  (such as  $4\text{MgCO}_3 \cdot \text{Mg}(\text{OH})_2 \cdot 5\text{H}_2\text{O}$ ),  $\text{ZnCO}_3$  (such as  
20  $3\text{Zn}(\text{OH})_2 \cdot 2\text{ZnCO}_3$ ),  $\text{CaCO}_3$ ,  $\text{Zn}_3(\text{C}_6\text{H}_5\text{O}_7)_2$ ,  $\text{Mg}(\text{OAc})_2$ ,  $\text{MgSO}_4$ ,  $\text{Zn}(\text{OAc})_2$ ,  $\text{ZnSO}_4$ ,  $\text{ZnCl}_2$ ,  $\text{MgCl}_2$  and  $\text{Mg}_3(\text{C}_6\text{H}_5\text{O}_7)_2$ . A suitable ratio of metal cation component-to-device is between about 1:99 to about 1:1 by weight. The optimum ratio depends upon the polymer and the metal cation utilized.

A polymeric matrix containing a dispersed metal cation component to  
25 modulate the release of a biologically active agent from the polymeric matrix is further described in U.S. Patent No. 5,656,297 issued to Bernstein *et al.* and co-pending PCT Patent Application PCT/US95/05511, the teachings of which are incorporated herein by reference in their entirety.

In a third aspect, the present invention provides a method of using the  
30 polymer-based sustained release device comprising providing a sustained delivery rate of active agent, in a subject, over a therapeutically useful period of time, by administering to the subject a dose of said polymer-based sustained release device.

The sustained release device of this invention can be administered to a human, or other animal, by injection, implantation (e.g, subcutaneously, intramuscularly, intraperitoneally, intracranially, intraocularly, intravaginally and intradermally), administration to mucosal membranes (e.g., intranasally or by means of a suppository), or *in situ* delivery (e.g. by enema or aerosol spray) to provide the desired dosage of an agent based on the known parameters for treatment with that agent of the various medical conditions.

Even though the invention has been described with a certain degree of particularity, it is evident that many alternatives, modifications, and variations will be apparent to those skilled in the art in light of the foregoing disclosure. Accordingly, it is intended that all such alternatives, modifications, and variations which fall within the spirit and scope of the invention be embraced by the defined claims.

The invention will now be further and specifically described by the following examples.

## EXEMPLIFICATION

### METHODS

The polymers employed in the following examples are described below:

Purchased from Boehringer Ingelheim

20 **RG 502H:** 10K MW, 50:50 Poly(D,L-lactide-co-glycolide) (PLGA), hydrophilic end groups

**RG 501H:** 5K MW, 50:50 Poly(D,L-lactide-co-glycolide) (PLGA), hydrophilic end groups

**R 104:** 5K MW, Poly(D,L-lactide)

25 Purchased from Birmingham Polymers, Inc., Birmingham Alabama

**Lot 112-43-1:** 5K MW, Poly(D,L-lactic acid)

### EXAMPLE 1: POLYMER SOLVENT METHOD

A polymer/active agent solution can be formed by dissolving an appropriate amount of polymer and active agent in a continuous phase comprising one or more

-22-

- polymer solvents which also solubilize the active agent. If more than one polymer solvent is employed both need not solubilize the active agent. The polymer/active agent solution can then be atomized into droplets which can be frozen. The solvent is then removed from the frozen droplets to form a polymer/active agent matrix by
- 5 diffusion of the polymer solvent into a polymer non-solvent phase, the cure phase. The cure phase can be comprised of a single solvent or a mixture of solvents. The particles are collected from the polymer non-solvent by filtration and residual polymer solvent and non-solvent are removed by evaporation. The dry product is sieved through an appropriately sized mesh so as to produce an injectable product.
- 10 The process can be summarized as follows:
- Formation of a polymer/active agent solution by dissolving PLGA copolymer (3-28%(w/v)) and active agent in DMSO.
  - Atomization of the polymer active agent solution by sonication, and freezing of the droplets by contact with liquid nitrogen.
  - 15 • Extraction of the polymer/active agent solvent in 80°C ethanol cure solvent, thereby forming a polymer active agent matrix.
  - Isolation of the particles from the cure solvent by filtration.
  - Removal of remaining solvents by evaporation.
  - Sizing of particles by passage through an appropriately sized mesh so as
  - 20 to produce an injectable product.

The "Particulate Method," referred to in Figures 1 and 3, is a process similar to that summarized above, but where the active agent is added to the polymer solution as a solid and remains in the solid or particulate form (i.e., does not dissolve) throughout the process.

25 EXAMPLE 1.1: 63% (w/w) PEPTIDE LOADED, PLGA  
MICROPARTICLES, ETHANOL CURE PHASE.

High load microparticles comprising PLGA and azaline B were prepared as follows:

- 1) A solution comprising DMSO (0.701 ml), PLGA (0.043 g) (10K MW, hydrophilic end groups) and azaline B acetate (0.185 g) was prepared by
- 30 mixing the components at room temperature.



-23-

- 2) The solution from step 1 was atomized by an ultrasonic atomizing probe (Sonics & Materials #630-0507) at a constant flow rate of 0.3 ml/minute.
- 3) The atomized droplets were frozen upon passage through a cold nitrogen gas phase and then into liquid nitrogen. The liquid nitrogen layer was placed  
5 over a frozen non-solvent phase (100% ethanol).
- 4) The liquid nitrogen layer containing the frozen droplets was allowed to evaporate at -80°C and the polymer/active agent solvent (DMSO) was extracted from the frozen droplets over an 18 hour incubation time at -80°C employing ethanol as the cure phase.
- 10 5) The microparticles were separated from the cure phase by filtration and freeze-dried.
- 6) The dry product was sieved through a 180 µm mesh sieve.

EXAMPLE 1.2: 63% (w/w) PEPTIDE LOADED, PLGA  
MICROPARTICLES, HEPTANE/ETHANOL CURE  
15 PHASE

- 1) A solution comprising DMSO (50.0 ml) and PLGA (5.0 g)(10K MW, hydrophilic end groups) copolymer was prepared at room temperature. To 3.0 ml of the polymer solution was added 0.233 g of azaline B acetate, and allowed to dissolve.
- 20 2) The solution from step 1 was atomized by an ultrasonic atomizing probe (Sonics & Materials #630-0507) at a constant flow rate of 0.3 ml/minute.
- 3) The atomized droplets were frozen upon passage through a cold nitrogen gas phase and then into liquid nitrogen. The liquid nitrogen layer was placed over a frozen non-solvent phase (75% heptane; 25% ethanol, v/v).
- 25 4) The liquid nitrogen layer containing the frozen droplets was allowed to evaporate at -80°C. The frozen non-solvent phase was allowed to melt at -80°C and the polymer/active agent solvent (DMSO) was extracted from the frozen droplets over an 18 hour incubation time at -80°C employing a mixture of heptane/ethanol (75:25) as the cure phase.
- 30 5) The microparticles were separated from the cure phase by filtration and freeze-dried.

- 6) The dry product was sieved through a 180  $\mu$ m mesh sieve.

Microparticles containing a 49% and a 41% load of azaline B (Figure 3) were also prepared employing the process of Example 1.1.

#### EXAMPLE 2: POLYMER SOLVENT/POLYMER NON-SOLVENT

- 5 The general procedure for the formation of microparticles using a mixture of polymer solvent/polymer non-solvent, is similar to the Polymer Solvent Method, described above, with the exception that the continuous phase comprises a polymer solvent/polymer non-solvent mixture. This method provides for the solubilization of active agents such as tRNA and ovalbumin, which are not readily soluble in polymer  
10 solvents. In the example described below the polymer non-solvent employed was water.

- The polymer solvent/water mixture was formulated such that the addition of water to the system increased the solubility of the active agent, but did not exceed the concentration at which substantial precipitation of the polymer would result. In  
15 addition, the polymer non-solvent can be used to predissolve the active agent; the resulting solution can then be added to the polymer solution such that a transient continuous phase results. The transient continuous phase can be further processed prior to precipitation of the active agent or polymer.

- A specific example of this method is the manufacture of a device comprising  
20 D,L-PLA (100% D,L-Poly(lactic acid), 5K MW) and ovalbumin at a 1% (w/w) load.

- 1) A 5% (w/v) D,L-PLA solution was prepared by dissolving D,L-PLA in DMSO at 50 mg D,L-PLA per ml of DMSO.
- 2) The active agent ovalbumin was dissolved in deionized water at a concentration of 100 mg/ml. 20 microliters of the aqueous solution was  
25 added to 39.6 ml of the polymer solution in a dropwise manner, with mixing.
- 3) The solution from step 2 was atomized by an air atomization. The atomized droplets are collected in a -70°C cure phase (ethanol), resulting in formation of the polymer matrix, with drug distributed throughout.
- 4) The microparticles were separated from the cure phase by filtration and  
30 freeze-dried.

- 5) The dry product was sieved through a 180  $\mu$ m mesh sieve.

EXAMPLE 3: POLYMER SOLVENT/POLYMER NON-SOLVENT

The general procedure for the formation of microparticles using a mixture of a polymer solvent and a polymer non-solvent, is similar to the Polymer Solvent

- 5 Method, described in detail above, with the exception that the continuous phase is comprised of a polymer solvent and a polymer non-solvent, for example, DMSO and ethanol. It is understood that the polymer non-solvent in this example is also an active agent non-solvent.

A specific example of this method is the manufacture of a sustained release  
10 device comprising PLGA and azaline B acetate at a 60% (w/w) load.

- 1) A 10% (w/v) solution of PLGA copolymer (10K MW, hydrophilic end groups) in a mixture of DMSO/ethanol (75:25 v/v) was prepared.
- 2) Azaline B acetate, in dry powder form was dissolved in the polymer solution at approximately room temperature to give a final concentration of 0.233g of  
15 azaline B acetate per ml of polymer solution.
- 3) The solution from step 2 was atomized by an ultrasonic atomizing probe (Sonics & Materials #630-0507) at a constant flow rate of 0.3 ml/minute.
- 4) The atomized droplets were frozen upon passage through a cold nitrogen gas phase and then into liquid nitrogen. The liquid nitrogen layer was placed  
20 over a frozen non-solvent phase (100% ethanol).
- 5) The liquid nitrogen layer containing the frozen droplets was allowed to evaporate at -80°C. The frozen non-solvent phase was allowed to melt at -80°C and the polymer solvent/active agent non-solvent (DMSO/ethanol) was extracted from the frozen droplets over an 18 hour incubation time at -80°C  
25 employing ethanol as the cure phase.
- 6) The microparticles were separated from the cure phase by filtration and freeze-dried.
- 7) The dry product was sieved through a 180  $\mu$ m mesh sieve.

30 Microparticles containing a 54% and a 68% load of azaline B (depicted in Figure 2) were also prepared employing this process.

EXAMPLE 4: POLYMER SOLVENT/ACTIVE AGENT NON-SOLVENT  
(OLIVE OIL CURE PHASE)

The general procedure for the formation of microparticles using a mixture of polymer solvent/active agent non-solvent, is similar to the Polymer Solvent Method,  
5 described in detail above, with the exception that the continuous phase comprises a polymer solvent/active agent non-solvent.

A specific example of this method, is the preparation of a sustained release device comprising PLGA and azaline B at a load 70% (w/w) active agent.

- 1) A 10% (w/v) solution of PLGA copolymer (10K MW, hydrophilic end  
10 groups) in a mixture of DMSO/acetone (80:20 v/v) was prepared.
- 2) Azaline B acetate, in dry powder form was dissolved in the polymer solution at room temperature to give a final concentration of 0.233 g of azaline B per ml of polymer solution.
- 3) The solution resulting from step 2 was atomized by an ultrasonic atomizing  
15 probe (Sonics & Materials #630-0507) at a constant flow rate of 0.3 ml/minute.
- 4) The atomized droplets were frozen upon contact with cold (4°C) olive oil.
- 5) The polymer solvent/active agent non-solvent (DMSO/acetone) was extracted from the frozen droplets over a 7 day incubation time at 4°C, with  
20 mixing.
- 6) The microparticles were separated from the oil by the formation of an emulsion in which the oil phase containing the microspheres was rapidly mixed with a 4X volume of a heptane/ethanol mixture (75:25 v/v). The microparticles were separated from the emulsion phase by filtration. The  
25 emulsion/filtration procedure was repeated 3 times.
- 7) The microparticles were separated from the final emulsion phase by filtration and freeze-dried.
- 8) The dry product was sieved through a 180 µm mesh sieve.

-27-

EXAMPLE 4.1: POLYMER SOLVENT/ACTIVE AGENT NON-SOLVENT-  
65% (w/w) LOAD (HEPTANE/ETHANOL 75:25 CURE  
PHASE)

- 1) A 10% (w/v) PLGA copolymer solution was prepared by dissolving PLGA  
5 copolymer (10K MW, hydrophilic end groups) in a mixture of  
DMSO/acetone (80:20 v/v).
- 2) Azaline B acetate, in dry powder form was dissolved in the polymer solution  
at room temperature to give a final concentration of 0.233 g of azaline B per  
ml of polymer solution.
- 10 3) The solution resulting from step 2 was atomized by an ultrasonic atomizing  
probe (Sonics & Materials #630-0507) at a constant flow rate of  
0.3 ml/minute.
- 4) The atomized droplets were frozen upon passage through a cold nitrogen gas  
phase and then into liquid nitrogen. The liquid nitrogen layer was placed  
15 over a frozen non-solvent phase (75:25% v/v heptane:ethanol).
- 5) The liquid nitrogen layer containing the frozen droplets was allowed to  
evaporate at -80°C. The frozen non-solvent phase was allowed to melt at  
-80°C and the polymer solvent/active agent non-solvent (DMSO/acetone)  
was extracted from the frozen droplets over an 18 hour incubation time at  
20 -80°C employing a mixture of heptane/ethanol (75:25) as the cure phase.
- 6) The microparticles were separated from the non-solvent phase by filtration  
and freeze-dried.
- 7) The dry product was sieved through a 180 µm mesh sieve.

EXAMPLE 4.2: POLYMER SOLVENT/ACTIVE AGENT NON-SOLVENT-  
25 68% (w/w) LOAD (ETHANOL CURE PHASE)

- 1) A 10% (w/v) PLGA copolymer solution was prepared by dissolving PLGA  
26 copolymer (10K MW, hydrophilic end groups) in a mixture of  
DMSO/acetone (80:20 v/v).
- 2) Azaline B acetate, in dry powder form was dissolved in the polymer solution  
30 at room temperature to give a final concentration of 0.233 g of azaline B per  
ml of polymer solution.

-28-

- 3) The solution resulting from step 2 was atomized by an ultrasonic atomizing probe (Sonics & Materials #630-0507) at a constant flow rate of 0.3 ml/minute.
- 4) The atomized droplets were frozen upon passage through a cold nitrogen gas phase and then into liquid nitrogen. The liquid nitrogen layer was placed over a frozen non-solvent phase (ethanol).
- 5) The liquid nitrogen layer containing the frozen droplets was allowed to evaporate at -80°C. The frozen non-solvent phase was allowed to melt at -80°C and the polymer solvent/active agent non-solvent (DMSO/acetone) was extracted from the frozen droplets over an 18 hour incubation time at -80°C employing ethanol as the cure phase.
- 6) The microparticles were separated from the non-solvent phase by filtration and freeze-dried.
- 7) The dry product was broken up by a gentle, manual grinding and passed through a 180 µm mesh sieve.

EXAMPLE 5: MANUFACTURE OF STERILE PRODUCT USING THE  
"MICROPARTICULATE METHOD"-POLYMER  
SOLVENT/ACTIVE AGENT NON-SOLVENT

The method can be used to produce sterile product by enabling the sterile filtration (0.2 µm) of the polymer/active agent solution, prior to further processing.

For example, the manufacture of a sterile 15% (w/w) loaded azaline B acetate/PLGA formulation was performed as follows:

- 1) A 20% (w/v) solution of PLGA copolymer (10K MW, hydrophilic end groups) in dichloromethane was prepared by dissolving 0.2 g of PLGA per ml of dichloromethane. The polymer solution (639 ml) was introduced into a sterile vessel, equipped with a rotor-stator homogenizer, using 0.22 µm filtration. The polymer solution was chilled to approximately -77°C.
- 2) Azaline B was dissolved in DMSO at a concentration of 12.5% (w/w) by dissolving 0.125 g of azaline B per gram of DMSO.

-29-

- 3) 135 g of the azaline B solution was introduced slowly into the sterile tank containing the polymer solution via 0.22  $\mu$ m filtration. The rotor-stator homogenizer was run immersed in the polymer solution and the temperature was maintained at approximately -77°C during the addition of the azaline B/DMSO solution.
- 4) The DMSO/azaline B solution freezes upon introduction to the cold polymer solution and is dispersed throughout the dichloromethane polymer solution by action of the rotor-stator homogenizer. As the DMSO and dichloromethane mix, peptide precipitates as a microsuspension.
- 5) The resulting microsuspension was atomized by air atomization and the droplets frozen by contact with liquid nitrogen.
- 6) The frozen droplets were mixed with an excess volume of ethanol upon which the DMSO and the dichloromethane were extracted to produce a polymer matrix with the active agent dispersed throughout.

The following Table summarizes the PLGA microparticles, prepared according to Examples 1 through 5. %Load and Encapsulation Efficiency were determined by analysis of the nitrogen content of the microparticles using a CE-440 Elemental Analyzer available from Exeter Analytical, Inc., Lowell, MA.

Example	Polymer/Active Phase	Process	Freeze Phase	Cure Phase	Product	Load (%w/w)	Encapsulation Efficiency (% Target)
1.1	DMSO	Atomization	Liquid Nitrogen	-80°C Ethanol	Microparticles	63	90
1.2	DMSO	Atomization	Liquid Nitrogen	-80°C Heptane/Ethanol 75:25	Microparticles	63	90
2	DMSO/Water	Atomization	Ethanol (<0°C)	-80°C Ethanol	Microparticles	1	67
3	DMSO/Ethanol	Atomization	Liquid Nitrogen	-80°C Ethanol	Microparticles	60	85
4	DMSO/Acetone	Atomization	Liquid Nitrogen	4°C Olive Oil	Microparticles	70	100
4.1	DMSO/Acetone	Atomization	Liquid Nitrogen	-80°C Heptane/Ethanol 75:25	Microparticles	65	93
4.2	DMSO/Acetone	Atomization	Liquid Nitrogen	-80°C Ethanol	Microparticles	68	97
5	Methylene Chloride/DMSO	Atomization "Micro-particulate"	Liquid Nitrogen	-80°C Ethanol	Microparticles	15 (Sterile)	100



*In Vivo Data*

## EXAMPLE 6: RAT ESTROUS MODEL

The Rat Estrous Cyclicity Model is described in detail in Hahn *et al.*, Biological Assays Utilized to Characterize LHRH and its Analogs. In: *LHRH and its Analogs, Contraception and Therapeutic Applications* (Eds. Vickery BH, Nestor JJ, and Hafez ESE), pp. 49-60. MTP Press Ltd, Lancaster, England, 1984, the contents of which are incorporated herein by reference. The model is used to assess the pharmacodynamic effect which an effective serum level of azaline B (at least 2.0 ng/ml), provided by the administration of a sustained release device of the invention, has on the estrous cycle of the rat. When the minimum effective concentration of azaline B is present in serum, the estrus phase of the estrous cycle of the rat is suppressed and the rat remains in the diestrus phase of the estrous cycle.

Microparticles containing an effective amount of azaline B were prepared according to the "Particulate Method," described above, and the methods of Examples 1 and 3. The presence of azaline B activity was measured as the percent of a test group which remained in the diestrus phase of the estrous cycle. Animals were subcutaneously injected with equal amounts of azaline B either encapsulated in a microparticle or unencapsulated. The injections employed a vehicle of 3% carboxymethyl cellulose (low viscosity) and 1% Tween-20 in saline. The results are depicted in Figures 1 and 2 which show a plot of the percent of animals per treatment group in diestrus for each formulation evaluated versus time. Figure 1 show that rats treated with the particulate formulations, were observed to begin cycling after 8-10 days. The rats treated with the microparticles prepared according to the method of the invention, specifically Examples 1 and 3, as shown in Figure 2 had a further delay in the onset of cycling, indicating the presence of an effective serum concentration for a longer period of time.

## EXAMPLE 7: EVALUATION OF AZALINE B SERUM LEVELS

Microparticles were processed using the "Particulate Method" described above and the methods of Examples 1 and 3. Animals were subcutaneously injected with equal amounts of azaline B either encapsulated in a microparticle or unencapsulated. The injections employed a vehicle of 3% carboxymethyl cellulose

(low viscosity) and 1% Tween-20 in saline. Serum levels (ng/ml) were determined at various times over a 28 day period and the results are shown in Figure 3 as a plot of the concentration of azaline B (ng/ml), versus time. Serum levels were determined using an electrochemiluminescent immunoassay method. In this method  
5 quantitation is performed using an antibody that is specific for azaline B, and concentration is determined by comparison to a standard curve.

Briefly, the animals were anesthetized with halothane and blood samples were collected via a lateral tail vein. The blood was clotted at room temperature, centrifuged at approximately 6000xg for about five minutes and stored at  
10 -70°C until analysis could be performed.

Figure 3 is a graph of the serum levels of azaline B versus time. The Figure demonstrates that the release profile of high load microparticles prepared according to the methods of Examples 1 and 3 was improved over that seen with microparticles prepared according to the "Particulate Method."

15 While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

## CLAIMS

What is claimed is:

1. A method of forming a polymer-based sustained release device comprising the steps of:
  - 5 a) forming a polymer/active agent solution by mixing a polymer, a continuous phase comprising one or more polymer solvents and an effective amount of an active agent wherein the polymer and active agent are present in relative concentrations such that the device contains about 50% by weight or more of active agent; and
  - 10 b) removing the continuous phase of step (a) thereby forming a solid polymer/active agent matrix.
2. The method of Claim 1 wherein the continuous phase comprises DMSO.
3. The method of Claim 1 further comprising the steps of:
  - 15 a) forming droplets of the polymer/active agent solution; and
  - b) freezing the droplets of the polymer/active agent solution wherein steps (a) and (b) are performed prior to removing the continuous phase; and
  - c) removing the continuous phase by extraction with an extraction solvent.
4. The method of Claim 3 wherein the droplets are microdroplets.
5. The method of Claim 4 wherein the extraction solvent employed in the  
20 extraction step is an oil.
6. The method of Claim 1 wherein the active agent is a peptide, an antigen or a small molecule drug.
7. The method of Claim 1 wherein the active agent is an LHRH analog.

8. The method of Claim 7 wherein the LHRH analog is azaline B.
9. The method of Claim 1 wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s,  
5 blends, and copolymers thereof.
10. A method for forming a polymer-based sustained release device comprising the steps of:
  - a) forming a polymer/active agent solution by mixing a polymer, an effective amount of an active agent and a continuous phase comprising a  
10 polymer solvent/polymer non-solvent mixture wherein the amount of non-solvent achieves solubilization of the active agent and does not cause substantial precipitation of the polymer; and
  - b) removing the continuous phase of step (a) from the polymer/active agent solution, thereby forming a solid polymer/active agent matrix.
- 15 11. The method of Claim 10 wherein the polymer solvent is DMSO.
12. The method of Claim 11 wherein the polymer non-solvent is ethanol.
13. The method of Claim 10 further comprising the steps of:
  - a) forming droplets of the polymer/active agent solution; and
  - b) freezing the droplets of the polymer/active agent solution, wherein said  
20 forming and freezing steps are performed prior to removing the continuous phase.
14. The method of Claim 13 wherein the droplets are microdroplets.
15. The method of Claim 10 wherein the active agent is a peptide, an antigen or a small molecule drug.

16. The method of Claim 10 wherein the active agent is an LHRH analog.
17. The method of Claim 16 wherein the LHRH analog is azaline B.
18. The method of Claim 10 wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s,  
5 poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.
19. A method for forming a polymer-based sustained release device comprising the steps of:
  - 10 a) forming a polymer/active agent solution by mixing a polymer, an effective amount of an active agent and a continuous phase comprising a polymer solvent/active agent non-solvent mixture wherein the amount of non-solvent achieves solubilization of the active agent and does not cause substantial precipitation of the polymer; and
  - 15 b) removing the continuous phase of step (a) from the polymer/active agent solution, thereby forming a solid polymer/active agent matrix.
20. The method of Claim 19 further comprising the steps of:
  - a) forming droplets of the polymer/active agent solution; and
  - 20 b) freezing the droplets of the polymer/active agent solution, wherein said forming and freezing steps are performed prior to removing the continuous phase.
21. The method of Claim 20 wherein the droplets are microdroplets.
22. The method of Claim 19 wherein the active agent is a peptide, an antigen or a small molecule drug.
23. The method of Claim 19 wherein the active agent is an LHRH analog.

24. The method of Claim 23 wherein the LHRH analog is azaline B.
25. The method of Claim 19 wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.
- 5
26. A method for forming a polymer-based sustained release device comprising the steps of:
- a) forming a polymer/active agent solution by mixing a polymer, an effective amount of an active agent, and a continuous phase comprising a polymer solvent/active agent non-solvent mixture wherein the amount of non-solvent achieves the active agent as a microparticulate in the continuous phase and does not cause substantial precipitation of the polymer; and
- 10
- b) removing the continuous phase of step (a) from the polymer/active agent solution, thereby forming a solid polymer/active agent matrix.
- 15
27. The method of Claim 26 further comprising the steps of:
- a) forming droplets of the polymer/active agent solution; and
- b) freezing the droplets of the polymer/active agent solution, wherein said forming and freezing steps are performed prior to removing the continuous phase.
- 20
28. The method of Claim 27 wherein the droplets are microdroplets.
29. The method of Claim 26 wherein the active agent is a peptide, an antigen or a small molecule drug.
30. The method of Claim 26 wherein the active agent is an LHRH analog.
- 25
31. The method of Claim 30 wherein the LHRH analog is azaline B.

32. The method of Claim 26 wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.
- 5 33. A method for forming a polymer-based sustained release device comprising the steps of:
- 10 a) forming a polymer/active agent solution by mixing a polymer, a continuous phase comprising one or more polymer solvents and an effective amount of an active agent wherein the polymer and active agent present in relative concentration such that the device contains about 50% by weight or more of the active agent;
- b) forming droplets of the polymer/active agent solution; and
- c) removing the continuous phase of step (a) from the polymer active agent solution thereby forming a solid polymer/active agent matrix.
- 15 34. The method of Claim 33 wherein the continuous phase comprises DMSO.
35. The method of Claim 34 further comprising the step of freezing the droplets of the polymer/active agent solution prior to removing the continuous phase wherein the continuous phase is removed by extraction.
- 20 36. The method of Claim 33 wherein the continuous phase is removed by evaporation.
37. The method of Claim 33 wherein the droplets are microdroplets.
38. The method of Claim 33 wherein the active agent is a peptide, an antigen or a small molecule drug.
39. The method of Claim 33 wherein the active agent is an LHRH analog.

40. The method of Claim 39 wherein the LHRH analog is azaline B.
41. The method of Claim 33 wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.
- 5
42. A method of forming a polymer-based sustained release device comprising the steps of:
- a) forming a polymer/active agent solution by mixing a polymer, a continuous phase comprising a polymer solvent/polymer non-solvent mixture and an effective amount of an active agent wherein the polymer and active agent are present in relative concentrations such that the device contains about 50% by weight or more of active agent, wherein the amount of non-solvent achieves solubilization of active agent and does not cause substantial precipitation of the polymer; and
- 10
- b) removing the continuous phase of step (a) from the polymer/active agent solution, thereby forming a solid polymer/active agent matrix.
- 15
43. The method of Claim 42 wherein the polymer solvent is DMSO.
44. The method of Claim 43 wherein the polymer non-solvent is ethanol.
45. The method of Claim 42 further comprising the steps of:
- 20
- a) forming droplets of the polymer/active agent solution; and
- b) freezing the droplets of the polymer/active agent solution, wherein said forming and freezing steps are performed prior to removing the continuous phase.
46. The method of Claim 45 wherein the droplets are microdroplets.



47. The method of Claim 42 wherein the active agent is a peptide, an antigen or a small molecule drug.
48. The method of Claim 42 wherein the active agent is an LHRH analog.
49. The method of Claim 48 wherein the LHRH analog is azaline B.
- 5 50. The method of Claim 42 wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.
- 10 51. A method for forming a polymer-based sustained release device comprising the steps of:
- 15 a) forming a polymer/active agent solution by mixing a polymer, an effective amount of an active agent wherein the polymer and active agent are present in relative concentrations such that the device contains about 50% by weight or more of active agent and a continuous phase comprising a polymer solvent/active agent non-solvent mixture wherein the amount of non-solvent achieves solubilization of the active agent and does not cause substantial precipitation of the polymer; and
- b) removing the continuous phase of step (a) from the polymer/active agent solution, thereby forming a solid polymer/active agent matrix.
- 20 52. The method of Claim 51 further comprising the steps of:
- a) forming droplets of the polymer/active agent solution; and
- b) freezing the droplets of the polymer/active agent solution, wherein said forming and freezing steps are performed prior to removing the continuous phase.
- 25 53. The method of Claim 52 wherein the droplets are microdroplets.

54. The method of Claim 51 wherein the active agent is a peptide, an antigen or a small molecule drug.
55. The method of Claim 52 wherein the active agent is an LHRH analog.
56. The method of Claim 55 wherein the LHRH analog is azaline B.
- 5 57. The method of Claim 51 wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.
- 10 58. A method for forming a polymer-based sustained release device comprising the steps of:
- 15 a) forming a polymer/active agent solution by mixing a polymer, DMSO and an effective amount of an active agent wherein the polymer and active agent are present in relative concentrations such that the device contains about 50% by weight or more of active agent; and
- 15 b) removing the DMSO of step (a) thereby forming a solid polymer/active agent matrix.
- 20 59. The method of Claim 58 further comprising the steps of:
- a) forming droplets of the polymer/active agent solution; and
- b) freezing the droplets of the polymer/active agent solution, wherein the forming and freezing steps are performed prior to removing the DMSO.
60. The method of Claim 59 wherein the DMSO is removed by extraction with an oil.
61. The method of Claim 59 wherein the DMSO is removed by extraction with an alkane/ethanol mixture.

62. The method of Claim 58 wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.
- 5 63. The method of Claim 58 wherein the active agent is a peptide, an antigen or a small molecule drug.
64. The method of Claim 58 wherein the active agent is an LHRH analog.
65. The method of Claim 64 wherein the LHRH analog is azaline B.
66. A polymer-based sustained release device produced by the steps of:
- 10 a) forming a polymer/active agent solution by mixing a polymer, a continuous phase comprising one or more polymer solvents and an effective amount of an active agent wherein the polymer and active agent are present in relative concentrations such that the device contains about 50% by weight or more of active agent;
- 15 b) forming droplets of the polymer/active agent solution;
- c) freezing the droplets of the polymer/active agent solution; and
- d) removing the continuous phase of step (a) thereby forming a solid polymer/active agent matrix.
67. The polymer-based sustained release device of Claim 66, wherein the device
- 20 is in the form of microparticles.
68. The polymer-based sustained release device of Claim 66, wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and
- 25 copolymers thereof.

69. The polymer-based sustained release device of Claim 66 wherein the active agent is a peptide, an antigen or a small molecule drug.
70. The polymer-based sustained release device of Claim 66 wherein the active agent is an LHRH analog.
- 5 71. The polymer-based sustained release device of Claim 70 wherein the LHRH analog is azaline B.
72. A method for providing a therapeutically effective level of an active agent in a subject for a sustained period, comprising administering to the subject a dose of the polymer-based sustained release device of Claim 66.
- 10 73. A polymer-based sustained release device produced by the steps of:
- a) forming a polymer/active agent solution by mixing a polymer, a continuous phase comprising a polymer solvent/polymer non-solvent mixture and an effective amount of an active agent wherein the polymer and active agent are present in relative concentrations such that the
  - 15 device contains about 50% by weight or more of active agent, and the amount of polymer non-solvent achieves solubilization of the active agent and does not cause substantial precipitation of the polymer;
  - b) forming droplets of the polymer/active agent solution;
  - c) freezing the droplets of the polymer/active agent solution; and
  - 20 d) removing the continuous phase of step (a) thereby forming a solid polymer/active agent matrix.
74. The polymer-based sustained release device of Claim 73, wherein the device is in the form of microparticles.
75. The polymer-based sustained release device of Claim 73, wherein the
- 25 polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s,

poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.

76. The polymer-based sustained release device of Claim 73 wherein the active agent is a peptide, an antigen or a small molecule drug.
- 5 77. The polymer-based sustained release device of Claim 73 wherein the active agent is an LHRH analog.
78. The polymer-based sustained release device of Claim 73 wherein the LHRH analog is azaline B.
- 10 79. A method for providing a therapeutically effective level of an active agent in a subject for a sustained period, comprising administering to the subject a dose of the polymer-based sustained release device of Claim 73.
80. A polymer-based sustained release device produced by the steps of:
- 15 a) forming a polymer/active agent solution by mixing a polymer, a continuous phase comprising a polymer solvent/active agent non-solvent mixture and an effective amount of an active agent wherein the polymer and active agent are present in relative concentrations such that the device contains about 50% by weight or more of active agent, and the amount of polymer non-solvent achieves solubilization of the active agent and does not cause substantial precipitation of the polymer;
- 20 b) forming droplets of the polymer/active agent solution;
- c) freezing the droplets of the polymer/active agent solution; and
- d) removing the continuous phase of step (a) thereby forming a solid polymer/active agent matrix.
81. The polymer-based sustained release device of Claim 80, wherein the device is in the form of microparticles.
- 25

82. The polymer-based sustained release device of Claim 80, wherein the polymer is selected from the group consisting of: poly(lactide)s, poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.
83. The polymer-based sustained release device of Claim 80 wherein the active agent is a peptide, an antigen, or a small molecule drug.
84. The polymer-based sustained release device of Claim 80 wherein the active agent is an LHRH analog.
85. The polymer-based sustained release device of Claim 80 wherein the LHRH analog is azaline B.
86. A method for providing a therapeutically effective level of an active agent in a subject for a sustained period, comprising administering to the subject a dose of the polymer-based sustained release device of Claim 80.
87. A polymer-based sustained release device produced by the steps of:
- a) forming a polymer/active agent solution by mixing a polymer, an effective amount of an active agent and a continuous phase comprising a polymer solvent/active agent non-solvent mixture wherein the polymer and active agent are present in relative concentrations such that the device contains about 50% by weight or more of active agent, and the amount of polymer non-solvent achieves the active agent as a microparticulate in the continuous phase and does not cause substantial precipitation of the polymer;
  - b) forming droplets of the polymer/active agent solution;
  - c) freezing the droplets of the polymer/active agent solution; and
  - d) removing the continuous phase of step (a) thereby forming a solid polymer/active agent matrix.

88. The polymer-based sustained release device of Claim 87, wherein the device is in the form of microparticles.
89. The polymer-based sustained release device of Claim 87, wherein the polymer is selected from the group consisting of: poly(lactide)s,  
5 poly(glycolide)s, poly(lactide-co-glycolide)s, poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s, blends, and copolymers thereof.
90. The polymer-based sustained release device of Claim 87 wherein the active agent is a peptide, an antigen or a small molecule drug.
- 10 91. The polymer-based sustained release device of Claim 87 wherein the active agent is an LHRH analog.
92. The polymer-based sustained release device of Claim 87 wherein the LHRH analog is azaline B.
- 15 93. A method for providing a therapeutically effective level of an active agent in a subject for a sustained period, comprising administering to the subject a dose of the polymer-based sustained release device of Claim 87.




FIG. 1



2/2




FIG. 2




FIG. 3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19603

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/16 A61K9/50 A61K38/09

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	EP 0 556 917 A (AKZO NV) 25 August 1993	19, 22-26, 29-32
Y	see the whole document	1, 4-10, 12, 15-18, 33, 36-42, 44, 47-57, 66-93
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 January 1999

Date of mailing of the international search report

26/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fischer, W

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19603

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	WO 90 13780 A (ENZYTECH INC) 15 November 1990	1,3-10, 13-33, 36-42, 45-57, 66-93
Y	see the whole document	2,11,12, 34,35, 43,44, 58-63
P,X, Y L	--- WO 97 42940 A (ALKERMES INC ;BURKE PAUL A (US)) 20 November 1997 "L": DOCUMENT SO QUOTED FOR ITS' CASTING DOUBT ON THE VALIDITY OF THE CONVENTION-PRIORITY CLAIM see the whole document	1,3-6,9
Y	--- WO 97 07788 A (ALKERMES INC ;LEE HYE JUNG (US); JOHNSON OLUFUNMI L (US); ZALE STE) 6 March 1997  see the whole document	2-4,9, 11-14, 20,21, 25,27, 28, 34-37, 43-49, 52, 58-63, 66-72
A	--- US 5 650 173 A (RAMSTACK J MICHAEL ET AL) 22 July 1997 see the whole document	11,34, 43,58
A	--- WO 95 29664 A (ALKERMES INC ;BERNSTEIN HOWARD (US); ZHANG YAN (US); KHAN M AMIN ( ) 9 November 1995	
A	--- EP 0 586 838 A (TANABE SEIYAKU CO) 16 March 1994	
A	--- EP 0 190 833 A (TAKEDA CHEMICAL INDUSTRIES LTD) 13 August 1986	
A	--- WO 96 19201 A (MERCK & CO INC ;RORK GERALD S (US); PIPKIN JAMES D (US)) 27 June 1996	
A	--- WO 96 12478 A (MERCK & CO INC ;RORK GERALD S (US); PIPKIN JAMES D (US)) 2 May 1996 -----	

# INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 98/ 19603

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 72, 79, 86, 93  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Although claims 72, 79, 86 AND 93 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----  
Claims Nos.: 72,79,86,93

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/19603

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0556917 A	25-08-1993	AT 138263 T	15-06-1996
		AU 658715 B	27-04-1995
		AU 3313493 A	19-08-1993
		CA 2089354 A	19-08-1993
		DE 69302721 D	27-06-1996
		DE 69302721 T	19-09-1996
		DK 556917 T	16-09-1996
		ES 2090836 T	16-10-1996
		FI 930672 A	19-08-1993
		GR 3020417 T	31-10-1996
		JP 5337360 A	21-12-1993
		MX 9300851 A	31-08-1994
		NZ 245914 A	24-02-1995
		US 5389379 A	14-02-1995
		ZA 9300929 A	10-09-1993
WO 9013780 A	15-11-1990	US 5019400 A	28-05-1991
		AU 621751 B	19-03-1992
		AU 5530990 A	29-11-1990
		CA 2030550 A	02-11-1990
		DK 424516 T	11-01-1993
		EP 0424516 A	02-05-1991
		JP 7039338 B	01-05-1995
		JP 3504389 T	26-09-1991
WO 9742940 A	20-11-1997	US 5817343 A	06-10-1998
		AU 2751797 A	05-12-1997
WO 9707788 A	06-03-1997	AU 7010496 A	19-03-1997
		EP 0850051 A	01-07-1998
US 5650173 A	22-07-1997	AU 684324 B	11-12-1997
		AU 1101095 A	06-06-1995
		AU 697887 B	22-10-1998
		AU 3683197 A	20-11-1997
		CA 2176716 A	26-05-1995
		EP 0729353 A	04-09-1996
		JP 9505308 T	27-05-1997
		WO 9513799 A	26-05-1995
		US 5654008 A	05-08-1997
WO 9529664 A	09-11-1995	US 5656297 A	12-08-1997
		AU 688506 B	12-03-1998
		AU 2467495 A	29-11-1995
		AU 7187898 A	30-07-1998
		CA 2189254 A	09-11-1995
		EP 0758227 A	19-02-1997
		JP 10504017 T	14-04-1998
EP 0586838 A	16-03-1994	JP 2651320 B	10-09-1997
		JP 6032732 A	08-02-1994
		AT 159854 T	15-11-1997
		CA 2099941 A	17-01-1994
		DE 69315026 D	11-12-1997
		DE 69315026 T	26-03-1998
		ES 2110544 T	16-02-1998
		GR 3025297 T	27-02-1998
		US 5556642 A	17-09-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/19603

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0190833 A	13-08-1986	CA 1260395 A	26-09-1989
		GR 860332 A	05-06-1986
		HK 137793 A	24-12-1993
		IE 58930 B	01-12-1993
		JP 1997858 C	08-12-1995
		JP 7020859 B	08-03-1995
		JP 62201816 A	05-09-1987
		LV 5822 A	20-10-1997
		PT 81980 B	01-07-1988
		SG 134693 G	31-03-1994
		US 4954298 A	04-09-1990
		US 5330767 A	19-07-1994
WO 9619201 A	27-06-1996	US 5582838 A	10-12-1996
		AU 693313 B	25-06-1998
		AU 4472696 A	10-07-1996
		CA 2206211 A	27-06-1996
		CN 1171048 A	21-01-1998
		CZ 9701895 A	18-02-1998
		EP 0801560 A	22-10-1997
		FI 972586 A	17-06-1997
		HU 77370 A	30-03-1998
		NO 972880 A	20-06-1997
		NZ 298994 A	28-10-1998
		PL 320792 A	27-10-1997
		SK 80597 A	04-02-1998
WO 9612478 A	02-05-1996	US 5543154 A	06-08-1996
		AU 4008995 A	15-05-1996